ArticleFrontiers in pharmacology2025
Rosa roxburghii Tratt juice ameliorates metabolic disorder in arsenicosis patients based on the analysis of untargeted plasma metabolomics.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative Metabolomics and Transcriptomics Analysis ofMolecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arsenic is an environmental metalloid contaminant known to induce multi-system and multi-organ damage, yet the precise toxicological mechanisms remain unclear. Moreover, effective low-toxicity interventions or treatments are lacking. This study aims to investigate the potential ameliorative effects of Rosa roxburghii Tratt juice (RRTJ) on metabolic disorders in arsenicosis patients, with a focus on plasma metabolite profiles. Using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS), we analyzed the plasma metabolic profiles of arsenicosis patients before and after RRTJ intervention. After RRTJ intervention, significant alterations were observed in the plasma levels of 61 metabolites, with 30 metabolites upregulated and 31 downregulated. These metabolites were predominantly involved in six key biological pathways, including taurine and hypotaurine metabolism, histidine metabolism, β-alanine metabolism, glycine, serine, and threonine metabolism, pentose and glucuronate interconversions, as well as cysteine and methionine metabolism. In conclusion, RRTJ intervention may effectively alleviate metabolic disorders associated with arsenic toxicity, potentially through its antioxidant, anti-inflammatory effects and regulation of methylation pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.